The Clarity study will assess the clinical and economic value of Aclarion’s Nociscan in spine surgery. The medtech company reached full funding for the trial with nearly $20 million, according to a Feb. 4 news release.
Nicholas Theodore, MD, of Baltimore-based Johns Hopkins, is leading the trial. Patients who are scheduled to have surgery for 1- or 2- level discogenic low back pain will be included, and they’ll all have a Nociscan before their procedures.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
